A PHASE II STUDY OF AK104, A BISPECIFIC ANTIBODY TARGETING PD-1 AND CTLA-4, IN PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA (NPC) WHO HAD PROGRESSED AFTER TWO OR MORE LINES OF CHEMOTHERAPYJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-1011OA
未登录.png){kind=icon}
未登录
